Related references
Note: Only part of the references are listed.Basophils Promote Tumor Rejection via Chemotaxis and Infiltration of CD8+ T Cells
Ibrahim M. Sektioglu et al.
CANCER RESEARCH (2017)
IL-1 maintains the redox balance by regulating glutaredoxin 1 expression during oral carcinogenesis
Xijuan Chen et al.
JOURNAL OF ORAL PATHOLOGY & MEDICINE (2017)
The transcriptome of lung tumor-infiltrating dendritic cells reveals a tumor-supporting phenotype and a microRNA signature with negative impact on clinical outcome
Lotte Pyfferoen et al.
ONCOIMMUNOLOGY (2017)
Osteoprotegerin mediates tumor-promoting effects of Interleukin-1beta in breast cancer cells
Stephanie Tsang Mui Chung et al.
MOLECULAR CANCER (2017)
Leflunomide for the treatment of trichodysplasia spinulosa in a liver transplant recipient
Rawan Kassar et al.
TRANSPLANT INFECTIOUS DISEASE (2017)
Intralesional treatment of metastatic melanoma: a review of therapeutic options
Benjamin Weide et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Lewis Lung Cancer Cells Promote SIGNR1( CD209b)-Mediated Macrophages Polarization Induced by IL-4 to Facilitate Immune Evasion
Xiaolong Yan et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2016)
IL6-induced metastasis modulators p-STAT3, MMP-2 and MMP-9 are targets of 3,3′-diindolylmethane in ovarian cancer cells
Minghua Zou et al.
CELLULAR ONCOLOGY (2016)
Breast cancer gene therapy using an adenovirus encoding human IL-2 under control of mammaglobin promoter/enhancer sequences
S. Chaurasiya et al.
CANCER GENE THERAPY (2016)
IL-4 / IL-13 mediated cell-to-cell fusion in prostate cancer progress
Berna Uygur et al.
CANCER RESEARCH (2016)
Myeloid-Derived Suppressor Cells Endow Stem-like Qualities to Breast Cancer Cells through IL6/STAT3 and NO/NOTCH Cross-talk Signaling
Dongjun Peng et al.
CANCER RESEARCH (2016)
Interleukin 33: an innate alarm for adaptive responses beyond Th2 immunity-emerging roles in obesity, intestinal inflammation, and cancer
Christian Schwartz et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2016)
T-Cell Therapy Enabling Adenoviruses Coding for IL2 and TNFα Induce Systemic Immunomodulation in Mice With Spontaneous Melanoma
Siri Tähtinen et al.
JOURNAL OF IMMUNOTHERAPY (2016)
The JAK inhibitor ruxolitinib impairs dendritic cell migration via off-target inhibition of ROCK
J. Rudolph et al.
LEUKEMIA (2016)
Interleukin-1 increases the risk of gastric cancer through induction of aberrant DNA methylation in a mouse model
Fung-Yu Huang et al.
ONCOLOGY LETTERS (2016)
IL-1 drives breast cancer growth and bone metastasis in vivo
Ingunn Holen et al.
ONCOTARGET (2016)
Potential therapeutic implications of IL-6/IL-6R/gp130-targeting agents in breast cancer
Tae-Hwe Heo et al.
ONCOTARGET (2016)
Recombinant soluble gp130 protein reduces DEN-induced primary hepatocellular carcinoma in mice
Jing Hong et al.
SCIENTIFIC REPORTS (2016)
A phase I clinical study of immunotherapy for advanced colorectal cancers using carcinoembryonic antigen-pulsed dendritic cells mixed with tetanus toxoid and subsequent IL-2 treatment
Ko-Jiunn Liu et al.
JOURNAL OF BIOMEDICAL SCIENCE (2016)
Deciphering the Cellular Targets of Bioactive Compounds Using a Chloroalkane Capture Tag
Rachel Friedman Ohana et al.
ACS CHEMICAL BIOLOGY (2015)
Synergistic Innate and Adaptive Immune Response to Combination Immunotherapy with Anti-Tumor Antigen Antibodies and Extended Serum Half-Life IL-2
Eric F. Zhu et al.
CANCER CELL (2015)
Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study
Riccardo Danielli et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
Targeting IL4/IL4R for the treatment of epithelial cancer metastasis
Katherine Venmar Bankaitis et al.
CLINICAL & EXPERIMENTAL METASTASIS (2015)
TAMS and IL-6 contribute to resistance to radiotherapy in oral squamous cell carcinoma
Y. Matsuoka et al.
INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY (2015)
Therapeutic DC vaccination with IL-2 as a consolidation therapy for ovarian cancer patients: a phase I/II trial
Soyoung Baek et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2015)
Inflammation and prostate cancer: the role of interleukin 6 (IL-6)
Daniel P. Nguyen et al.
BJU INTERNATIONAL (2014)
Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15
Yang Xu et al.
BLOOD (2014)
Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumour angiogenesis: anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour-stroma interaction
T. Nagasaki et al.
BRITISH JOURNAL OF CANCER (2014)
IL4 Receptor ILR4α Regulates Metastatic Colonization by Mammary Tumors through Multiple Signaling Pathways
Katherine T. Venmar et al.
CANCER RESEARCH (2014)
Interleukin-6 and its receptors: A highly regulated and dynamic system
Janina Wolf et al.
CYTOKINE (2014)
The IL-2 cytokine family in cancer immunotherapy
Geok Choo Sim et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2014)
Siltuximab: First Global Approval
Anthony Markham et al.
DRUGS (2014)
Tumor-Associated Macrophages Produce Interleukin 6 and Signal via STAT3 to Promote Expansion of Human Hepatocellular Carcinoma Stem Cells
Shanshan Wan et al.
GASTROENTEROLOGY (2014)
IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients
Geok Choo Sim et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
The origin of cancer stem cells
Hien T. Dang et al.
JOURNAL OF HEPATOLOGY (2014)
IL-2: The First Effective Immunotherapy for Human Cancer
Steven A. Rosenberg
JOURNAL OF IMMUNOLOGY (2014)
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
Lisa A. Beck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Targeting interleukin-6 in inflammatory autoimmune diseases and cancers
Xin Yao et al.
PHARMACOLOGY & THERAPEUTICS (2014)
Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19-IL2 Results in Sustained Clinical and Systemic Immunologic Responses
Benjamin Weide et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Interleukin-4 receptor alpha overexpression in human bladder cancer correlates with the pathological grade and stage of the disease
Bharat H. Joshi et al.
CANCER MEDICINE (2014)
Feasibility of IL-15-activated cytokine-induced killer cell infusions after haploidentical stem cell transplantation
E. Rettinger et al.
BONE MARROW TRANSPLANTATION (2013)
Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer
S. Mitsunaga et al.
BRITISH JOURNAL OF CANCER (2013)
Identification of Liver Cancer Progenitors Whose Malignant Progression Depends on Autocrine IL-6 Signaling
Guobin He et al.
CELL (2013)
Complete Remission Achieved With Single Agent CNTO 328, an Anti-IL-6 Monoclonal Antibody, in Relapsed and Refractory Myeloma
Ajai Chari et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2013)
Interleukin-15 in Gene Therapy of Cancer
Maria C. Ochoa et al.
CURRENT GENE THERAPY (2013)
Osteoprotegerin: Multiple partners for multiple functions
Marc Baud'huin et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2013)
Possible Role for Tocilizumab, an Anti-Interleukin-6 Receptor Antibody, in Treating Cancer Cachexia
Katsutoshi Ando et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Therapeutic modulators of STAT signalling for human diseases
Gabriella Miklossy et al.
NATURE REVIEWS DRUG DISCOVERY (2013)
Dupilumab in Persistent Asthma with Elevated Eosinophil Levels
Sally Wenzel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Role of Interleukin-1β in Radiation-Enhancement of MDA-MB-231 Breast Cancer Cell Invasion
Benoit Paquette et al.
RADIATION RESEARCH (2013)
Targeting Interleukin-4 in Asthma: Lost in Translation?
Tania Maes et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2012)
Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia
Alireza Eghtedar et al.
BLOOD (2012)
Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients
Laszlo G. Radvanyi et al.
CLINICAL CANCER RESEARCH (2012)
Regulation of inflammation by interleukin-4: a review of alternatives
Irina G. Luzina et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2012)
IL-15-stimulated CD3/CD19-depleted stem-cell boosts in relapsed pediatric patients after haploidentical SCT
M. M. Pfeiffer et al.
LEUKEMIA (2012)
From IL-2 to IL-37: the expanding spectrum of anti-inflammatory cytokines
Jacques Banchereau et al.
NATURE IMMUNOLOGY (2012)
Targeting interleukins to treat severe asthma
David Gibeon et al.
EXPERT REVIEW OF RESPIRATORY MEDICINE (2012)
Reprogramming CD19-Specific T Cells with IL-21 Signaling Can Improve Adoptive Immunotherapy of B-Lineage Malignancies
Harjeet Singh et al.
CANCER RESEARCH (2011)
Adipose derived stem cells (ASCs) isolated from breast cancer tissue express IL-4, IL-10 and TGF-beta 1 and upregulate expression of regulatory molecules on T cells: Do they protect breast cancer cells from the immune response?
Mahboobeh Razmkhah et al.
CELLULAR IMMUNOLOGY (2011)
A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer
Trevor J. Bayliss et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2011)
Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis
Alen Ostojic et al.
FUTURE ONCOLOGY (2011)
Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor
Alfonso Quintas-Cardama et al.
INVESTIGATIONAL NEW DRUGS (2011)
IL-1α and IL-1β Recruit Different Myeloid Cells and Promote Different Stages of Sterile Inflammation
Peleg Rider et al.
JOURNAL OF IMMUNOLOGY (2011)
Interleukin-6 signalling regulates vascular endothelial growth factor-C synthesis and lymphangiogenesis in human oral squamous cell carcinoma
Satoru Shinriki et al.
JOURNAL OF PATHOLOGY (2011)
gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma
Douglas J. Schwartzentruber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Inflammasome activation and IL-1β target IL-1α for secretion as opposed to surface expression
Antonia Fettelschoss et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
The Anti-Interleukin-6 Antibody Siltuximab Down-Regulates Genes Implicated inTumorigenesis in Prostate Cancer Patients From a Phase I Study
Jayaprakash Karkera et al.
PROSTATE (2011)
A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer
J-F Rossi et al.
BRITISH JOURNAL OF CANCER (2010)
Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells
Yue Wang et al.
CANCER LETTERS (2010)
Simultaneous Blockade of Multiple Immune System Inhibitory Checkpoints Enhances Antitumor Activity Mediated by Interleukin-15 in a Murine Metastatic Colon Carcinoma Model
Ping Yu et al.
CLINICAL CANCER RESEARCH (2010)
Interleukin-6 in bone metastasis and cancer progression
Tasnim Ara et al.
EUROPEAN JOURNAL OF CANCER (2010)
IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion
Vasilena Gocheva et al.
GENES & DEVELOPMENT (2010)
Interleukin-2 and Inflammation Induce Distinct Transcriptional Programs that Promote the Differentiation of Effector Cytolytic T Cells
Matthew E. Pipkin et al.
IMMUNITY (2010)
Leflunomide: a drug with a potential beyond rheumatology
Sven Teschner et al.
IMMUNOTHERAPY (2010)
Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells
Carsten Krieg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma
C. K. Oh et al.
EUROPEAN RESPIRATORY REVIEW (2010)
Breast Cancer Cell Lines Contain Functional Cancer Stem Cells with Metastatic Capacity and a Distinct Molecular Signature
Emmanuelle Charafe-Jauffret et al.
CANCER RESEARCH (2009)
Humanized Anti-Interleukin-6 Receptor Antibody Suppresses Tumor Angiogenesis and In vivo Growth of Human Oral Squamous Cell Carcinoma
Satoru Shinriki et al.
CLINICAL CANCER RESEARCH (2009)
Clinical and Biological Efficacy of Recombinant Human Interleukin-21 in Patients with Stage IV Malignant Melanoma without Prior Treatment: A Phase IIa Trial
Ian D. Davis et al.
CLINICAL CANCER RESEARCH (2009)
A High-Affinity Fully Human Anti-IL-6 mAb, 1339, for the Treatment of Multiple Myeloma
Mariateresa Fulciniti et al.
CLINICAL CANCER RESEARCH (2009)
Antitumor effect of humanized anti-interleukin-6 receptor antibody (tocilizumab) on glioma cell proliferation Laboratory investigation
Mareina Kudo et al.
JOURNAL OF NEUROSURGERY (2009)
Targeting Interleukin 6 Signaling Suppresses Glioma Stem Cell Survival and Tumor Growth
Hui Wang et al.
STEM CELLS (2009)
Targeted therapies in multiple myeloma
Efstathios Kastritis et al.
TARGETED ONCOLOGY (2009)
The opposite effects of IL-15 and IL-21 on CLL B cells correlate with differential activation of the JAK/STAT and ERK1/2 pathways
Daniela de Totero et al.
BLOOD (2008)
IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy
Christian S. Hinrichs et al.
BLOOD (2008)
IL-6-Induced Stimulation of c-Myc Translation in Multiple Myeloma Cells Is Mediated by Myc Internal Ribosome Entry Site Function and the RNA-Binding Protein, hnRNP A1
Yijiang Shi et al.
CANCER RESEARCH (2008)
Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system
Sherry L. LaPorte et al.
CELL (2008)
Apoptosis resistance in epithelial tumors is mediated by tumor-cell-derived interleukin-4
M. Todaro et al.
CELL DEATH AND DIFFERENTIATION (2008)
The blockade of IL-6 signaling in rational drug design
Yasuo Adachi et al.
CURRENT PHARMACEUTICAL DESIGN (2008)
IL-4-induced Stat6 activities affect apoptosis and gene expression in breast cancer cells
Wen Jie Zhang et al.
CYTOKINE (2008)
Is interleukin-1 a good or bad 'guy' in tumor immunobiology and immunotherapy?
Ron N. Apte et al.
IMMUNOLOGICAL REVIEWS (2008)
Phase III Trial Comparing Concurrent Biochemotherapy With Cisplatin, Vinblastine, Dacarbazine, Interleukin-2, and Interferon Alfa-2b With Cisplatin, Vinblastine, and Dacarbazine Alone in Patients With Metastatic Malignant Melanoma (E3695): A Trial Coordinated by the Eastern Cooperative Oncology Group
Michael B. Atkins et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
IL-1 trap go-ahead
Mark Ratner
NATURE BIOTECHNOLOGY (2008)
IL-2- and IL-15-induced activation of the rapamycin-sensitive mTORC1 pathway in malignant CD4+ T lymphocytes
Michal Marzec et al.
BLOOD (2008)
Overexpression of E-cadherin and beta-catenin proteins in metastatic prostate cancer cells in bone
Baisakhi Saha et al.
PROSTATE (2008)
IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland
Pasquale Sansone et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome
Christophe Ginestier et al.
CELL STEM CELL (2007)
Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4
Matilde Todaro et al.
CELL STEM CELL (2007)
Inflammation, atrophy, and gastric cancer
James G. Fox et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Inflammation and breast cancer - Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression
David G. DeNardo et al.
BREAST CANCER RESEARCH (2007)
Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer
Stefan Rose-John et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2006)
Differential regulation of T-cell growth by IL-2 and IL-15
Georgina H. Cornish et al.
BLOOD (2006)
Tumor cell-derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer
Olga Vasiljeva et al.
CANCER RESEARCH (2006)
IL-2 administration increases CD4+CD25hi Foxp3+ regulatory T cells in cancer patients
M Ahmadzadeh et al.
BLOOD (2006)
Role of osteoprotegerin (OPG) in cancer
I Holen et al.
CLINICAL SCIENCE (2006)
The role of interleukin 1 in growth and metastasis of human cancer cenografts
DM Elaraj et al.
CLINICAL CANCER RESEARCH (2006)
Inflammation-associated immune suppression in cancer: The roles played by cytokines, chemokines and additional mediators
A Ben-Baruch
SEMINARS IN CANCER BIOLOGY (2006)
Tumor-driven evolution of immunosuppressive networks during malignant progression
Ryungsa Kim et al.
CANCER RESEARCH (2006)
Paradoxical roles of the immune system during cancer development
KE de Visser et al.
NATURE REVIEWS CANCER (2006)
Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: A phase I/II study
AV Maker et al.
ANNALS OF SURGICAL ONCOLOGY (2005)
Immune cell migration in inflammation: present and future therapeutic targets
AD Luster et al.
NATURE IMMUNOLOGY (2005)
Exploiting the PI3K/AKT pathway for cancer drug discovery
BT Hennessy et al.
NATURE REVIEWS DRUG DISCOVERY (2005)
Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma:: results of a pilot study including biological aspects
JF Rossi et al.
BONE MARROW TRANSPLANTATION (2005)
High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer
S Bellone et al.
GYNECOLOGIC ONCOLOGY (2005)
IL-6, its receptors and its relationship with bcl-2 and bax proteins in infiltrating and in situ human breast carcinoma
I Garcia-Tuñón et al.
HISTOPATHOLOGY (2005)
The structure of interleukin-2 complexed with its alpha receptor
M Rickert et al.
SCIENCE (2005)
Interieukin-6 regulation of prostate cancer cell growth
Z Culig et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2005)
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma
ME Dudley et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
eInterleukin-4 enhances proliferation of human pancreatic cancer cells: evidence for autocrine and paracrine actions
O Prokopchuk et al.
BRITISH JOURNAL OF CANCER (2005)
The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: Results from cancer and leukemia group B 9480
DJ George et al.
CLINICAL CANCER RESEARCH (2005)
Interleukin-6 and C-reactive protein in metastatic renal cell carcinoma
O Altundag et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma
DF McDermott et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function
R Zeng et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Signal transducer and activator of transcription 6 (Stat6) and CD1: inhibitors of immunosurveillance against primary tumors and metastatic disease
S Ostrand-Rosenberg et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2004)
The immunobiology of cancer immunosurveillance and immunoediting
GP Dunn et al.
IMMUNITY (2004)
Interleukin-6 is responsible for drug resistance and anti-apoptotic effects in prostatic cancer cells
YS Pu et al.
PROSTATE (2004)
Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: Prognostic value of interleukin-6-from the Groupe Francais d'Immunotherapie
S Negrier et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Suppression of cancer cachexia by 20S,21-epoxy-resibufogenin-3-acetate -: a novel nonpeptide IL-6 receptor antagonist
A Enomoto et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer
JC Yang et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
mRNA of MUC2 is stimulated by IL-4, IL-13 or TNF-α through a mitogen-activated protein kinase pathway in human colon cancer cells
J Iwashita et al.
IMMUNOLOGY AND CELL BIOLOGY (2003)
Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence
S Cavalieri et al.
BLOOD (2003)
In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells
G Dontu et al.
GENES & DEVELOPMENT (2003)
IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist
S Nakae et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms
EM El-Omar et al.
GASTROENTEROLOGY (2003)
Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway
LH Wei et al.
ONCOGENE (2003)
Circulating interleukin-6 predicts survival in patients with metastatic breast cancer
R Salgado et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Cytokine traps: multi-component, high-affinity blockers of cytokine action
AN Economides et al.
NATURE MEDICINE (2003)
Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes
A Mantovani et al.
TRENDS IN IMMUNOLOGY (2002)
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes
ME Dudley et al.
SCIENCE (2002)
Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma
TK Hart et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2002)
Proinflammatory cytokine IL-1β promotes tumor growth of Lewis lung carcinoma by induction of angiogenic factors:: In vivo analysis of tumor-stromal interaction
Y Saijo et al.
JOURNAL OF IMMUNOLOGY (2002)
NF-κB in cancer:: From innocent bystander to major culprit
M Karin et al.
NATURE REVIEWS CANCER (2002)
Overexpression of IL-6 but not IL-8 increases paclitaxel resistance of U-20S human osteosarcoma cells
Z Duan et al.
CYTOKINE (2002)
The role of cytokines in regulating estrogen synthesis: implications for the etiology of breast cancer
A Purohit et al.
BREAST CANCER RESEARCH (2002)
Interleukin-6 and the network of several cytokines in multiple myeloma: An overview of clinical and experimental data
VM Lauta
CYTOKINE (2001)
Inflammation and cancer: back to Virchow?
F Balkwill et al.
LANCET (2001)
Therapeutic potential of inhibition of the NF-kappa B pathway in the treatment of inflammation and cancer
Y Yamamoto et al.
JOURNAL OF CLINICAL INVESTIGATION (2001)
Cutting edge: STAT6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma
S Ostrand-Rosenberg et al.
JOURNAL OF IMMUNOLOGY (2000)
Spontaneous rejection of poorly immunogenic P1.HTR tumors by Stat6-deficient mice
AK Kacha et al.
JOURNAL OF IMMUNOLOGY (2000)
A combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete response rates in advanced multiple myeloma
P Moreau et al.
BRITISH JOURNAL OF HAEMATOLOGY (2000)
Interleukin-1 polymorphisms associated with increased risk of gastric cancer
EM El-Omar et al.
NATURE (2000)
Interleukin-6 blood level is associated with circulating carcinoembryonic antigen and prognosis in patients with colorectal cancer
C Belluco et al.
ANNALS OF SURGICAL ONCOLOGY (2000)
Cytokines IL-1 beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNF alpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel
RT Penson et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2000)
Interleukin-1 family expression in human breast cancer: Interleukin-1 receptor antagonist
LJ Miller et al.
CANCER INVESTIGATION (2000)
Share Paper
